Association study of miR-146a G>C polymorphisms with susceptibility of hepatocellular carcinoma in the Chinese population: a Meta-analysis

Abstract

Abstract:

AIM:This Meta-analysis including only Chinese primary hepatocellular carcinoma (PHC) patients was conducted to assess the associations of miR-146a G>C(rs2910164) with PHC risk. METHODS: Literatures were researched using PubMed, Cochrane Library, Wanfang and China National Knowledge Infrastructure(CNKI) databases to identify relevant studies from the establishment of database to March 2017. Stata software (version 12.0) was used to check odds ratio (OR) and 95% confidence interval (CI). RESULTS: A total of nine published case studies were included in this Meta-analysis, which included 3 937 cases and 5 025 controls. The result suggested SNP was associated with PHC risk in dominant model ［(GG+GC)/CC］［1.26, (1.12-1.41), P=0.00］, recessive model［GG/(GC+CC)］［1.23,(1.12-1.34), P=0.00］and allele model(G/C)［1.17, (1.10-1.25), P=0.00］under random effect and fixed effect. Heterogeneity was found among and within studies. Meta regression indicated that the effect size was positively correlated with sample region in dominant model. Subgroup analysis revealed a significant association of this SNP with PHC risk among studies of people from middle-eastern and western area and people using PCR-RFLP, but no such association was found using Non-PCR-RFLP and in studies of people from southwestern area. Three genotypes presented stable sensitivity and absent publication bias. CONCLUSION: miR-146a G>C is associated with PHC risk in Chinese population, and G allelic increased the PHC risk, this SNP may be a biomarker for PHC occurrence.

Key words: Meta-analysis, primary hepatocellular carcinoma, miR-146a G>C

CLC Number:

R195.1

LI Yun, LI Bingsheng, ZHANG Weifang, LI Yixiu, LI Chun, PENG Juan, LAI Xin, ZHU Jing, XU Ruilai, XIONG Aizhen. Association study of miR-146a G>C polymorphisms with susceptibility of hepatocellular carcinoma in the Chinese population: a Meta-analysis[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(7): 779-786.

References

［1］Farazi PA, Depinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment［M］. Nat Rev Cancer， 2006，6(9):674-687.
［2］Jazdzewski K, Murray EL, Schoenberg DR,et al. Common SNP in Pre-miR-146a decreases mature miRNA expression and predisposes to papillary thyroid carcinoma［J］. Proc Natl Acad Sci U S A， 2008，105(20):7269-7274.
［3］麦艾. miR-146a异常表达及其单核苷酸多态位点rs2910164与胃癌易感性的相关研究［D］. 广州医科大学,2014.
［4］Hu Z, Liang J, Shen H,et al. Common genetic variants in pre-microRNAs were associated with increased risk of breast cancer in chinese women［J］.Hum Mutat，2009，30(1):79-84.
［5］Cong N, Chen H, Bu WZ,et al.MiR-146a G>C Polymorphisms and risk of hepatocellular carcinoma in a chinese population［J］. Tumour Biol，2014，35(6):5669-5673.
［6］Chen JJ, Cao XD,Zhang HY. miR-146a rs2910164 Polymorphism is associated with hepatocellular carcinoma: a meta-analysis［M］.Int J Clin ExP Med，2015，8(9):15852-15856.
［7］Chen M, Luo F, Yu J,et al. Common functional polymorphism within miR-146a and miR-196a-2 as susceptibility loci for hepatocellularcarcinoma: An updated Meta-analysis［M］. Meta Gene，2015， 7:40-47.
［8］Sun N, Sun X, Chen B, et al. MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer［J］. Cancer Chemother Pharmacol，2010，65(3):437-446.
［9］Harbord RM, Egger M, Sterne JA,et al.A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints［J］. Stat Med，2006，25(20):3443-3457.
［10］Qi JH, Wang J, Chen J, et al. High-resolution melting analysis reveals genetic polymorphisms in microRNAs confer hepatocellular carcinoma risk in chinese patients［J］.BMC Cancer，2014，14:643.
［11］Zhou B, Dong LP, Zhao LF,et al.Association between miR-146aG>C and miR-196a2C>T polymorphisms and the risk of hepatocellularcarcinoma in a Chinese population［J］.Tumour Biol，2014 35(8):7775-7780.
［12］郝玉霞. miR196α基因多态性在原发性肝癌发生发展中的作用及机制研究［D］.山西医科大学, 2014.
［13］Kou JT, Fan H, He Q,et al. Association between four common microRNA polymorphisms and the risk of hepatocellular carcinoma and HBV infection［J］. Oncol Lett，2014，8(3):1255-1260.
［14］Shan YF, Huang YH, Zhang QY,et al. miR-499A>G rs3746444 and miR-146aG>C expression and hepatocellular carcinoma risk in the chinese population［J］. Genet Mol Res，2013，12(4):5365-5371.
［15］Li X, Li K, Wu Z.Association of four common SNPs in microRNA polymorphisms with the risk of hepatocellular carcinoma［J］. Int J Clin ExP Pathol，2015，8(8):9560-9566.
［16］Zhang J, Wang R, Liu J,et al. Association between single nucleotide polymorphisms in miRNA196a-2 and miRNA146a and susceptibility to hepatocellular carcinoma in a chinese population［J］. Asian Pac J Cancer Prev，2013，14(11):6427-6431.
［17］Akkiz H, Bayram S, Sandokol M,et al.No association of pre-microRNA-146a rs2910164 polymorphism and risk of hepatocellular carcinomadevelopment in Turkish population:a case-control study［J］. Gene，2011，486(1-2):104-109.
［18］张新伟,潘善东,沈洪兵,等.微小RNA前体区域基因多态与肝细胞肝癌遗传易感性关联的研究［J］.中华预防医学杂志, 2011, 45(3):239-243.
［19］Zeng Y, Sun QM, Wang B,et al. Correlation between pre-miR-146a C/G polymorphism and gastric cancer risk in chinese population［J］. World J Gastroenterol，2010，16(28):3578-3583.
［20］李玉春.MicroRNA相关单核苷酸多态性与原发性肝癌遗传易感性研究［D］. .郑州大学,2012.
［21］王文章.miR-146a单核苷酸多态与肝癌遗传易感性的关联研究及肿瘤相关microRNA的微阵列分析的研究［D］.复旦大学,2011.
［22］黄琼华.miRNA-146a、miRNA-196a2基因多态性与广西壮族人群原发性肝癌的相关性研究［D］.广西医科大学,2013.
［23］Li D, Peng JJ, Zhang T,et al.Genetic variations in microRNA genes and susceptibility to hepatocellular carcinoma［J］. Genet Mol Res，2015，14(1):1926-1931.
［24］Xiang Y, Fan S, Zhang LP,et al.Association of the microRNA-499 variants with susceptibility to hepatocellular carcinoma in a Chinese population［J］. Mol Biol ReP，2012，39(6):7019-7023.
［25］Xu T, Zhu Y, Zhuang SM,et al. A functional polymorphism in the miR-146a gene is associated with the risk for hepatocellular carcinoma［J］.Carcinogenesis， 2008，29(11):2126-2131.
［26］Zhou J, Lv R, Wang L,et al.Association between two genetic variants in miRNA and primary liver cancer risk in the chinese population［J］.DNA Cell Biol，2012，31(4):524-530.
［27］Yan P, Xia M, Gong L,et al.Predictive role of miR-146a rs2910164 (C>G), miR-149 rs2292832 (T>C), miR-196a2 rs11614913 (T>C) and miR-499 rs3746444 (T>C) in the development of hepatocellular carcinoma［J］. Int J Clin ExP Pathol，2015，8(11):15177-15183.
［28］Guan DX, Shi J, Xie D,et al.Sorafenib enriches epithelial cell adhesion molecule-positive tumor initiating cells and exacerbates asubtype of hepatocellular carcinoma through TSC2-AKT cascade［J］. Hepatology，2015，62(6):1791-1803.
［29］Li J, Xu Y, Chen GQ,et al.Cbx4 governs HIF-1α to potentiate angiogenesis of hepatocellular carcinoma by its SUMO E3 ligase activity［J］. Cancer Cell，2014，25(1):118-131.
［30］Liepelt A, Tacke F. Stromal cell-derived factor-1 (SDF-1) as a target in liver diseases［J］. Am J Physiol Gastrointest Liver Physiol，2016，;311(2):G203-209.
［31］Su R, Nan H, Guo H,et al. Associations of components of PTEN/AKT/mTOR pathway with cancer stem cell markers and prognosticvalue of these biomarkers in hepatocellular carcinoma［J］. Hepatol Res，2016，46(13):1380-1391.
［32］Zhang Z, Zhang Y, Sun XX, et al. microRNA-146a inhibits cancer Metastasis by downregulating VEGF through dual pathways in hepatocellular carcinoma［J］. Mol Cancer， 2015，14:5.
［33］阮萃才.环境因素与肝癌［J］.上海环境科学,1986(5):35-40.
［34］Iakova P, Timchenko L, Timchenko NA. Intracellular signaling and hepatocellular carcinoma［J］.Semin Cancer Biol，2011，21(1):28-34.
［35］Teoh NC. Proliferative drive and liver carcinogenesis: too much of a good thing［J］? J Gastroenterol Hepatol， 2009 ，24(12):1817-1825.
［36］Sidhu K, Kapoor NR, Kumar V,et al. The "Macro" world of microRNAs in hepatocellular carcinoma［J］.Front Oncol，2015，5:68.
［37］黄宇,黄迪,古维立,等.非乙非丙型肝癌与HBV/HCV相关肝癌的临床特点及预后影响因素分析［J］.临床肝胆病杂志，2016.32(3): 514-517.
［38］Stickel N, Prinz G, Pfeifer D,et al.miR-146aregulates the TRAF6/TNF-axis in donor T cells during GVHD［J］.Blood，2014，124(16):2586-2595.
［39］Ramkaran P, Khan S, Phulukdaree A, et al.miR-146a polymorphism influences levels of miR-146a, IRAK-1, and TRAF-6 in young patients with coronary artery disease［J］.Cell Biochem Biophys，2014，68(2):259-266.

[1]	MA Guangli, ZHANG Jing. Application of quantitative pharmacology in vaccine research and de-velopment: overview and prospect [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 315-322.
[2]	YE Hongbo, SONG Yangyang, XUE Ling, RUI Jianzhong. Meropenem population pharmacokinetic model for the Chinese elderly established by model-based META analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 984-990.
[3]	YU Zhaolei, BAI Jianling, YU Hao, ZHAO Yang. Development of tools for clinical trial information retrieval and Meta-analysis based on R-Shiny: Taking non-small cell lung cancer as an example [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 984-991.
[4]	CHEN Wenjun, RUAN Zourong, XIANG Xiaoqiang. Development and application progress of physiologically based pharmacokinetic modeling and its combined use with other modeling methods [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(3): 299-305.
[5]	LI Lujin, DING Junjie, LIU Dongyang, WANG Xipei, DENG Chenhui, JI Shangmin, CHEN Wenjun, MA Guangli, WANG Kun, SHENG Yucheng, XU Ling, PEI Qi, CHEN Yuancheng, CHEN Rui, SHI Jun, LI Gailing, WANG Yaning, WANG Yuzhu, XIE Haitang, ZHOU Tianyan, FANG Yi, ZHANG Jing, JIAO Zheng, HU Bei, ZHENG Qingshan. General considerations of model-based meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(11): 1250-1267.
[6]	SHAO Yaojun, ZHENG Tong,WANG Yanqiu,LIU Ling,YAO Yingshui. Nimodipine combined with flunarizine for preventing and treating migraine: A Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(6): 646-652.
[7]	WANG Weiyu, YU Hao. Effects of gray drugs in patients with coronary heart disease: A network Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(3): 301-307.
[8]	WU Jiaqi, YANG Qiaowen, CHEN Xiumin, HUANG Runyue, HUANG Qingchun, ZHAO Yue, WU Xiaodong. Efficacy and safety of iguratimod combined with methotrexate in rheumatoid arthritis: A systematic review and Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(10): 1132-1140.
[9]	ZHANG Xiaoyu, FANG Zhengmei, YAO Yingshui. Association of leptin and leptin receptor gene polymorphisms with hypertension: a Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(8): 910-916.
[10]	RONG Guoyi, WANG Shumei, TANG Mo. Efficacy of reducing phlegm with traditional Chinese medicine on non-small cell lung cancer: a Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(7): 787-794.
[11]	WU Changjuan, TANG Tiansheng. Efficacy of Zhenyuan capsule as adjuvant therapy for chronic heart failure: a Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(3): 299-304.
[12]	CHEN Jiaren, CUI Yudi, TIAN Hao, WANG Hao. Vortioxetine for major depressive disorder: a systematic review and meta-analysis of randomized controlled trials [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(1): 52-59.
[13]	HANG Yongfu, LU Guoyuan, SHEN Lei, GAO Jie, QIAO Qing, LI Ming, SHA Wengang, ZHOU Ling, DING Xiaoliang, XIE Cheng. Efficacy and safety of leflunomide for IgA nephropathy：A meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(1): 60-67.
[14]	HU Jing, ZHU Jun-rong, YU Feng. Efficacy and safety of warfarin dosage algorithms in clinical application:A Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(3): 296-303.
[15]	WU Yan, WU Cui-fang, WANG Jiang-lin. Efficacy and safety of lixisenatide in comparison to placebo: a meta-analysis of randomized controlled trials [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(2): 167-174.